XOMA (NASDAQ:XOMA) Raised to Hold at StockNews.com

XOMA (NASDAQ:XOMA) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Friday.

Separately, HC Wainwright reiterated a “buy” rating and set a $104.00 price objective on shares of XOMA in a report on Wednesday.

XOMA Stock Down 0.9 %

XOMA stock opened at $20.88 on Friday. The company has a 50 day moving average of $24.37 and a 200-day moving average of $27.13. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a twelve month low of $19.92 and a twelve month high of $35.00. The stock has a market capitalization of $250.12 million, a PE ratio of -6.00 and a beta of 1.00.

XOMA (NASDAQ:XOMA) last announced its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The company had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. On average, equities research analysts anticipate that XOMA will post -1.41 EPS for the current fiscal year.

Insider Buying and Selling at XOMA

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 7.20% of the company’s stock.

Institutional Investors Weigh In On XOMA

Several hedge funds have recently bought and sold shares of XOMA. Woodline Partners LP raised its stake in XOMA by 63.9% in the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock valued at $4,107,000 after buying an additional 60,927 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of XOMA by 238.9% during the 4th quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock worth $318,000 after acquiring an additional 8,522 shares during the last quarter. Barclays PLC raised its stake in XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after acquiring an additional 8,447 shares during the period. Los Angeles Capital Management LLC acquired a new stake in XOMA during the 4th quarter valued at $206,000. Finally, Renaissance Technologies LLC boosted its position in XOMA by 89.8% during the fourth quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 7,619 shares during the period. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.